Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors

Trial Profile

A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs CPI 1205 (Primary) ; Ipilimumab
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Pelvic cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ORIOn-E
  • Sponsors Constellation Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2019 Planned End Date changed from 1 Jun 2020 to 1 Dec 2019.
    • 04 Jan 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2019.
    • 04 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top